Influence of recombinant human platelet-derived growth factor on lateral ridge augmentation using biphasic calcium phosphate and guided bone regeneration: a histomorphometric study in dogs.
BACKGROUND
The present study investigated the effects of recombinant human platelet-derived growth factor-BB (rhPDGF-BB) on initial bone formation following lateral ridge augmentation using biphasic calcium phosphate (BCP) in combination with a native collagen membrane (CM) in dogs.


METHODS
Eight chronic-type mandibular lateral ridge defects in four beagle dogs (two defects each) were randomly allocated in a split-mouth design to BCP + rhPDGF-BB + CM (test) or BCP + CM (control). After 3 weeks, dissected blocks were prepared for immunohistochemical (angiogenesis-transglutaminase II [TG]) and histomorphometric analysis (e.g., augmented area [AA] and mineralized tissue [MT]). The biologic activity of rhPDGF-BB soak-loaded BCP was verified by means of alkaline phosphatase and lactate dehydrogenase assays in a SaOs-2-osteoblast-like cell culture.


RESULTS
Both groups exhibited a comparable pattern of blood vessel and bone formation that mainly originated from the adjacent alveolar bone. However, test sites revealed a pronounced TG antigen reactivity, which was associated with statistically significant higher mean AA (8.5 +/- 0.9 mm(2) versus 7.1 +/- 1.1 mm(2)) and MT (2.7 +/- 0.9 mm(2) versus 1.7 +/- 0.8 mm(2)) values compared to the control sites (P <0.05; paired t test).


CONCLUSIONS
BCP + rhPDGF-BB might have the potential to support the initial stages of guided bone regeneration at chronic-type lateral ridge defects.
Schwarz
Frank
F
Department of Oral Surgery, Heinrich Heine University, Düsseldorf, Germany. frank.schwarz@med.uni-duesseldorf.de
Sager
Martin
M
Ferrari
Daniel
D
Mihatovic
Ilja
I
Becker
Jürgen
J
D000469:Alkaline Phosphatase / Q000032:analysis; D016301:Alveolar Bone Loss / Q000601:surgery; D000539:Alveolar Process / Q000187:drug effects / Q000473:pathology; D000540:Alveolar Ridge Augmentation / Q000379:methods*; D000818:Animals; D000077214:Becaplermin; D001672:Biocompatible Materials; D001861:Bone Regeneration / Q000187:drug effects*; D018786:Bone Substitutes / Q000627:therapeutic use*; D002130:Calcium Phosphates / Q000627:therapeutic use*; D002478:Cells, Cultured; D003094:Collagen; D004285:Dogs; D019204:GTP-Binding Proteins / Q000032:analysis; D016557:Guided Tissue Regeneration, Periodontal / Q000379:methods*; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000032:analysis; D008297:Male; D008336:Mandibular Diseases / Q000601:surgery; D008567:Membranes, Artificial; D018919:Neovascularization, Physiologic / Q000502:physiology; D010006:Osteoblasts / Q000187:drug effects / Q000473:pathology; D010011:Osteocytes / Q000187:drug effects / Q000473:pathology; D010012:Osteogenesis / Q000187:drug effects; D010982:Platelet-Derived Growth Factor / Q000627:therapeutic use*; D000091345:Protein Glutamine gamma Glutamyltransferase 2; D020574:Proto-Oncogene Proteins c-sis; D011897:Random Allocation; D011994:Recombinant Proteins; D011503:Transglutaminases / Q000032:analysis
D001672:Biocompatible Materials; D018786:Bone Substitutes; D002130:Calcium Phosphates; D008567:Membranes, Artificial; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins; D000077214:Becaplermin; D003094:Collagen; C020243:calcium phosphate; D007770:L-Lactate Dehydrogenase; D000091345:Protein Glutamine gamma Glutamyltransferase 2; D011503:Transglutaminases; D000469:Alkaline Phosphatase; D019204:GTP-Binding Proteins